Scarica l'app Stockscreener
6.93
2.51%
0.17
Precedente Chiudi:
$6.76
Aprire:
$6.77
Volume 24 ore:
1.30M
Relative Volume:
1.39
Capitalizzazione di mercato:
$606.45M
Reddito:
-
Utile/perdita netta:
$-95.90M
Rapporto P/E:
-5.25
EPS:
-1.32
Flusso di cassa netto:
$-79.09M
1 W Prestazione:
-1.70%
1M Prestazione:
+15.50%
6M Prestazione:
+73.03%
1 anno Prestazione:
-11.94%
Intervallo 1D:
$6.59
$7.07
Intervallo di 1 settimana:
$6.2324
$7.16
Portata 52W:
$1.865
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Nome
Terns Pharmaceuticals Inc
Settore
Industria
Telefono
650-525-5535 EXT.101
Indirizzo
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Confronta TERN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
6.93 | 591.57M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-10-31 | Iniziato | Oppenheimer | Outperform |
| 2023-06-22 | Iniziato | Mizuho | Buy |
| 2023-06-07 | Iniziato | Jefferies | Buy |
| 2023-05-31 | Iniziato | ROTH MKM | Buy |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-02-07 | Iniziato | UBS | Buy |
| 2022-09-12 | Iniziato | H.C. Wainwright | Neutral |
| 2021-09-14 | Ripresa | Goldman | Buy |
| 2021-03-02 | Iniziato | Cowen | Outperform |
| 2021-03-02 | Iniziato | Goldman | Buy |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Terns Pharmaceuticals Inc Borsa (TERN) Ultime notizie
RSI Suggests Rebound May Be Near in Terns Pharmaceuticals Inc.CEO Change & Safe Entry Trade Reports - newsyoung.net
Terns Pharmaceuticals Inc. Nearing Breakout Level After BounceJuly 2025 Closing Moves & AI Driven Price Forecasts - thegnnews.com
Institutional Tools Highlight Unusual Flow in Terns Pharmaceuticals Inc.July 2025 Momentum & Real-Time Volume Triggers - beatles.ru
Terns Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Breakouts & Weekly High Return Opportunities - Newser
Key metrics from Terns Pharmaceuticals Inc.’s quarterly dataJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
Terns Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Setups & AI Enhanced Trading Signals - Newser
Can trapped investors hope for a rebound in Terns Pharmaceuticals Inc.July 2025 Sector Moves & Stepwise Trade Execution Plans - Newser
Applying chart zones and confluence areas to Terns Pharmaceuticals Inc.July 2025 Price Swings & Consistent Growth Equity Picks - Newser
Sentiment analysis tools applied to Terns Pharmaceuticals Inc.2025 Risk Factors & Growth-Oriented Investment Plans - Newser
Best data tools to analyze Terns Pharmaceuticals Inc. stockMarket Sentiment Review & Growth Focused Investment Plans - Newser
Using AI based signals to follow Terns Pharmaceuticals Inc.July 2025 Setups & Weekly Watchlist for Hot Stocks - Newser
Multi asset correlation models including Terns Pharmaceuticals Inc.Weekly Market Outlook & Verified Swing Trading Watchlists - Newser
Is Terns Pharmaceuticals Inc. stock bottoming outJuly 2025 Spike Watch & High Yield Stock Recommendations - Newser
Is Terns Pharmaceuticals Inc. a play on infrastructure spendingWeekly Profit Report & Free Safe Capital Growth Stock Tips - thegnnews.com
Will earnings trigger a reversal in Terns Pharmaceuticals Inc.Weekly Investment Summary & Free Long-Term Investment Growth Plans - Newser
Terns Pharmaceuticals Inc. At Critical Juncture — Bounce or BreakdownPortfolio Profit Report & Technical Pattern Recognition Alerts - metal.it
Terns Pharmaceuticals Inc (TERN) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
What institutional flow reveals about Terns Pharmaceuticals Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - Newser
What makes Terns Pharmaceuticals Inc. stock price move sharplyMarket Activity Summary & Fast Gain Swing Alerts - Newser
Is It Too Late to Sell Terns Pharmaceuticals Inc.2025 Market Sentiment & Real-Time Market Sentiment Reports - classian.co.kr
Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data - Investing.com Nigeria
Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data By Investing.com - Investing.com South Africa
Analyzing Sangamo Therapeutics (NASDAQ:SGMO) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Analyzing drawdowns of Terns Pharmaceuticals Inc. with statistical toolsJuly 2025 Trade Ideas & Fast Moving Stock Trade Plans - Newser
Heatmap analysis for Terns Pharmaceuticals Inc. and competitorsLong Term Stock Planner with Safety Checks - Newser
Does Terns Pharmaceuticals Inc. show high probability of reboundFree Breakout Confirmation With Entry Tracker - Newser
Terns Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Custom strategy builders for tracking Terns Pharmaceuticals Inc.Downside Control Plan With Support Analysis - Newser
William Blair Has Positive Outlook of TERN FY2025 Earnings - Defense World
How Terns Pharmaceuticals Inc. stock performs during market volatilityFree Portfolio Diversification Stock Ideas - Newser
Terns Pharmaceuticals Inc Azioni (TERN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Terns Pharmaceuticals Inc Azioni (TERN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gengos Andrew | Chief Financial Officer |
Jun 27 '25 |
Buy |
3.93 |
10,000 |
39,283 |
25,000 |
| Burroughs Amy L. | Chief Executive Officer |
Jun 25 '25 |
Buy |
3.87 |
23,314 |
90,230 |
47,083 |
| Gengos Andrew | Chief Financial Officer |
Jun 13 '25 |
Buy |
3.73 |
10,000 |
37,350 |
10,000 |
| Gengos Andrew | Chief Financial Officer |
Jun 16 '25 |
Buy |
3.95 |
5,000 |
19,732 |
15,000 |
| Kuriakose Emil | Chief Medical Officer |
Apr 01 '25 |
Sale |
2.49 |
952 |
2,366 |
53,317 |
| Jung Melita Sun | Chief Business Officer |
Nov 30 '24 |
Buy |
5.11 |
2,250 |
11,498 |
2,250 |
| Burroughs Amy L. | Chief Executive Officer |
Nov 30 '24 |
Buy |
5.11 |
510 |
2,606 |
19,609 |
| Kuriakose Emil | Chief Medical Officer |
Jan 02 '25 |
Sale |
5.71 |
4,481 |
25,607 |
54,269 |
| Vignola Mark J. | Chief Financial Officer |
Jan 06 '25 |
Sale |
5.80 |
9,059 |
52,500 |
74,752 |
| Vignola Mark J. | Chief Financial Officer |
Jan 02 '25 |
Sale |
5.72 |
8,129 |
46,524 |
83,811 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):